Table 3.

Logistic regression analysis evaluating independent predictors of failure to HIVEC

Variables	B*	SE	Wald	p-value	OR [Exp(B)]	95% CI
Age	-.017	.037	.213	.644	.983	.914–1.057
Gender  Male (reference)  Female	– -.292	– .694	– .177	– .674	– .747	– .192–2.911
Smoking status  Non-smoker  Smoker  Ex-smoker	– .583 -.275	– .661 .921	– .778 .089	– .378 .766	– 1.791 .760	– .491–6.539 .125–4.624
BMI	.067	.069	.937	.333	1.069	.934–1.224
Diabetes  No (reference)  Yes	– -.041	– .858	– .002	– .962	– .959	– .179–5.153
Number of tumors  Single (reference)  Multiple	– .749	– .724	– 1.069	– .301	– 2.114	– .511–8.743
Tumor size  <3 cm (reference)  ≥3 cm	– 1.512	– .691	– 4.780	– .029	– 4.535	– 1.169–17.586
Recurrence rate  ≤1/year (reference)  >1/year	– 1.727	– .814	– 4.495	– .034	– 5.622	– 1.139–27.739
Pathologic state  Ta (HG) (reference)  T1 (HG)	– -.214	– .961	– .049	– .824	– .808	– .123–5.315
Concomitant CIS  No (reference)  Yes	– 2.407	– 1.164	– 4.278	– .039	– 11.097	– 1.134–108.568
Tumor on RE-TURB  No (reference)  Yes	– -1.289	– .956	– 1.820	– .177	– .276	– .042–1.793
Previously treated with MMC  No (reference)  Yes	– -1.259	– .895	– 1.979	– .159	– .284	– .049–1.641
BCG classes  BCG intolerance (reference)  BCG refractory  BCG relapse  BCG unresponsive	– 1.747 2.217 2.619	– 1.165 1.382 1.323	– 2.250 2.575 3.917	– .134 .109 .048	– 5.738 9.183 13.726	– .585–56.269 .612–137.778 1.026–183–696
Drug used  Mitomycin (reference)  Epirubicin	– -1.261	– .891	– 2.004	– .157	– .283	– .049–1.624

HIVEC – hyperthermic intravesical chemotherapy; RE-TURB – re-transurethral resection of bladder; MMC – mitomycin C; BCG – bacillus Calmette – Guérin

^*intercept;

SE – standard error; OR – odds ratio [exponentiation of the B coefficient]; CI – confidence interval; BMI – body mass index; HG – high-grade; CIS – carcinoma in situ